Ad
related to: new antipsychotic approved prescription products available
Search results
Results from the WOW.Com Content Network
Antipsychotics by class Generic name Brand names Chemical class ATC code Typical antipsychotics; Acepromazine: Atravet, Acezine: phenothiazine: N05AA04
Saphris – atypical antipsychotic used to treat schizophrenia and bipolar disorder; Serax – anti-anxiety medication of the benzodiazepine class, often used to help during detoxification from alcohol or other addictive substances; Serentil (mesoridazine) – an antipsychotic drug used in the treatment of schizophrenia [1]
As with many of the atypical antipsychotics, blonanserin can elicit cardio metabolic risks. While the side effects of blonanserin – such as weight gain, cholesterol and triglyceride levels, glucose levels and other blood lipid levels – do not differ greatly from other atypical antipsychotics, the specificity of blonanserin appears to elicit milder side effects, with less weight gain in ...
Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist, [5] but rather is a selective antagonist or inverse agonist of the serotonin 5-HT 2A receptor and to a lesser extent of the serotonin 5-HT 2C receptor. [3] Pimavanserin was first approved for medical use in 2016. [3] It was approved as a generic medication in 2024. [6]
Lumateperone, sold under the brand name Caplyta, is an atypical antipsychotic medication of the butyrophenone class. It is approved for the treatment of schizophrenia as well as bipolar depression, as either monotherapy or adjunctive therapy (with lithium or valproate). [2] It is developed by Intra-Cellular Therapies, licensed from Bristol ...
[2] [10] This mechanism of action is unique among available antipsychotics, which generally antagonize dopamine receptors (especially dopamine D 2 receptor). [11] [12] Ulotaront is a full agonist of the human TAAR1 with an EC 50 Tooltip half-maximal effective concentration of 140 nM and an E max Tooltip maximal efficacy of 101.3%. [12]
Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. [3] [4] [5] It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia.
In September 2024, it was approved for medical use in the United States. [ 1 ] [ 2 ] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors , which has long been the standard of care.
Ad
related to: new antipsychotic approved prescription products available